Plasma MR-proANP levels are associated with carotid intima-media thickness in the general community: The KORA F4 study

Atherosclerosis

Volumn 230, Issue 2, 2013, Pages 235-241

  Then, C ^a,b   Kowall, B ^c   Lechner, A ^a,b   Meisinger, C ^d   Heier, M ^d   Koenig, W ^e   Peters, A ^d   Thiery, J ^f   Rathmann, W ^c   Seissler, J ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Diabetes; Intima media thickness; Metabolic syndrome; MR proANP; Natriuretic peptide; Vasoactive hormones

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; PRO ATRIAL NATRIURETIC HORMONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ECHOGRAPHY; FEMALE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL;

DIABETES; INTIMA-MEDIA THICKNESS; METABOLIC SYNDROME; MR-PROANP; NATRIURETIC PEPTIDE; VASOACTIVE HORMONES;

ATHEROSCLEROSIS; ATRIAL NATRIURETIC FACTOR; AUTOMATION; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLUCOSE TOLERANCE TEST; HORMONES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; REGRESSION ANALYSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 84884516319     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.07.047     Document Type: Article

References (44)

1. Zimmet P., Magliano D., Matsuzawa Y., Alberti G., Shaw J. The metabolic syndrome: a global public health problem and a new definition. JAtheroscler Thromb 2005, 12(6):295-300.
2. Tesauro M., Cardillo C. Obesity, blood vessels and metabolic syndrome. Acta Physiol (Oxf) 2011, 203(1):279-286.
3. DeFronzo R.A., Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011, 108(3 Suppl.):3B-24B.
4. Savoia C., Volpe M., Alonzo A., Rossi C., Rubattu S. Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clin Sci (Lond) 2010, 118(4):231-240.
5. Kuhn M. Endothelial actions of atrial and B-type natriuretic peptides. Br J Pharmacol 2012, 166(2):522-531.
6. Lafontan M., Moro C., Berlan M., Crampes F., Sengenes C., Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 2008, 19(4):130-137.
7. Ropero A.B., Soriano S., Tuduri E., et al. The atrial natriuretic peptide and guanylyl cyclase-A system modulates pancreatic beta-cell function. Endocrinology 2010, 151(8):3665-3674.
8. Lainscak M., von Haehling S., Anker S.D. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol 2009, 132(3):303-311.
9. Masson S., Latini R., Carbonieri E., et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010, 12(4):338-347.
10. Maier C., Clodi M., Neuhold S., et al. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care 2009, 32(10):1890-1895.
11. Melander O., Newton-Cheh C., Almgren P., et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAm Med Assoc 2009, 302(1):49-57.
12. Kablak-Ziembicka A., Przewlocki T., Sokolowski A., Tracz W., Podolec P. Carotid intima-media thickness, hs-CRP and TNF-alpha are independently associated with cardiovascular event risk in patients with atherosclerotic occlusive disease. Atherosclerosis 2011, 214(1):185-190.
13. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004, 109(5):594-600.
14. Olsen M.H., Hansen T.W., Christensen M.K., et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005, 46(4):660-666.
15. Rubattu S., Sciarretta S., Ciavarella G.M., et al. Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. JHypertens 2007, 25(4):833-839.
16. Magnusson M., Jujic A., Hedblad B., et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. JClin Endocrinol Metab 2012, 97(2):638-645.
17. Everett B.M., Cook N.R., Chasman D.I., et al. Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women. Clin Chem 2013, 59(3):557-565.
18. Polak J.F., Pencina M.J., Pencina K.M., O'Donnell C.J., Wolf P.A., D'Agostino R.B. Carotid-wall intima-media thickness and cardiovascular events. NEngl J Med 2011, 365(3):213-221.
19. Kavousi M., Elias-Smale S., Rutten J.H., et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 2012, 156(6):438-444.
20. Vlachopoulos C., Ioakeimidis N., Terentes-Printzios D., et al. Amino-terminal pro-C-type natriuretic peptide is associated with arterial stiffness, endothelial function and early atherosclerosis. Atherosclerosis 2010, 211(2):649-655.
21. Schnabel R.B., Wild P.S., Schulz A., et al. Multiple endothelial biomarkers and noninvasive vascular function in the general population: the Gutenberg Health Study. Hypertension 2012, 60(2):288-295.
22. Meisinger C., Ruckert I.M., Rathmann W., et al. Retinol-binding protein 4 is associated with prediabetes in adults from the general population: the Cooperative Health Research in the Region of Augsburg (KORA) F4 Study. Diabetes Care 2011, 34(7):1648-1650.
23. Rathmann W., Strassburger K., Heier M., et al. Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabet Med 2009, 26(12):1212-1219.
24. Rathmann W., Haastert B., Icks A., et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003, 46(2):182-189.
25. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
26. Touboul P.J., Hennerici M.G., Meairs S., et al. Mannheim intima-media thickness consensus. Cerebrovasc Dis 2004, 18(4):346-349.
27. Kowall B., Ebert N., Then C., et al. Associations between blood glucose and carotid intima-media thickness disappear after adjustment for shared risk factors: the KORA F4 study. PLoS One 2012, 7(12):e52590.
28. Seissler J., Feghelm N., Then C., et al. Vasoregulatory peptides pro-endothelin-1 and pro-adrenomedullin are associated with metabolic syndrome in the population-based KORA F4 study. Eur J Endocrinol 2012, 167(6):847-853.
29. Morgenthaler N.G., Struck J., Thomas B., Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004, 50(1):234-236.
30. McKie P.M., Cataliotti A., Sangaralingham S.J., et al. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc 2011, 86(12):1154-1160.
31. Nambi V., Chambless L., Folsom A.R., et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. JAm Coll Cardiol 2010, 55(15):1600-1607.
32. Targonska-Stepniak B., Drelich-Zbroja A., Majdan M. The relationship between carotid intima-media thickness and the activity of rheumatoid arthritis. JClin Rheumatol 2011, 17(5):249-255.
33. Li X., Yang X.C., Sun Q.M., Chen X.D., Li Y.C. Brain natriuretic peptide and copeptin levels are associated with cardiovascular disease in patients with chronic kidney disease. Chin Med J (Engl) 2013, 126(5):823-827.
34. Reinhard H., Wiinberg N., Hansen P.R., et al. NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis. Cardiovasc Diabetol 2011, 10:71.
35. Yazici D., Yavuz D.G., Toprak A., Deyneli O., Akalin S. Impaired diastolic function and elevated Nt-proBNP levels in type 1 diabetic patients without overt cardiovascular disease. Acta Diabetol 2013, 50(2):155-161.
36. Saritas T., Tascilar E., Abaci A., et al. Importance of plasma N-terminal pro B-type natriuretic peptide, epicardial adipose tissue, and carotid intima-media thicknesses in asymptomatic obese children. Pediatr Cardiol 2010, 31(6):792-799.
37. Wang T.J., Larson M.G., Keyes M.J., Levy D., Benjamin E.J., Vasan R.S. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007, 115(11):1345-1353.
38. Khaleghi M., Saleem U., Morgenthaler N.G., et al. Plasma midregional pro-atrial natriuretic peptide is associated with blood pressure indices and hypertension severity in adults with hypertension. Am J Hypertens 2009, 22(4):425-431.
39. Sarzani R., Dessi-Fulgheri P., Paci V.M., Espinosa E., Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. JEndocrinol Invest 1996, 19(9):581-585.
40. Bartels E.D., Nielsen J.M., Bisgaard L.S., Goetze J.P., Nielsen L.B. Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice. Endocrinology 2010, 151(11):5218-5225.
41. Uehlinger D.E., Weidmann P., Gnadinger M.P., et al. Increase in circulating insulin induced by atrial natriuretic peptide in normal humans. JCardiovasc Pharmacol 1986, 8(6):1122-1129.
42. Verspohl E.J., Bernemann I.K. Atrial natriuretic peptide (ANP)-induced inhibition of glucagon secretion: mechanism of action in isolated rat pancreatic islets. Peptides 1996, 17(6):1023-1029.
43. Moro C., Klimcakova E., Lolmede K., et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 2007, 50(5):1038-1047.
44. Thakore A.H., Guo C.Y., Larson M.G., et al. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). Am J Cardiol 2007, 99(11):1598-1602.